"The data presented at this meeting continue to support ampreloxetine's potential to deliver a consistent and durable benefit to MSA patients with nOH with a favorable safety and tolerability profile," said Roy Freeman, MBChB, Professor of Neurology, Director, Center for Autonomic and Peripheral Nerve Disorders, Beth Israel Deaconess Medical Center. "MSA is a rare, debilitating disease and many MSA patients suffer from symptoms related to poor blood pressure control that have a significant impact on their quality of life."1
Data will be presented in a poster session on Monday, August 28, 2023, starting at 1:00 PM Central European Time (7:00 AM EDT / 4:00 AM PDT / 11:00 AM GMT):
Category: Clinical Trials and Therapy in Movement Disorders (non-PD) (non-Dystonia)
- Freeman R, et al. Abstract 7
An Analysis of Subgroups of Multiple System Atrophy Patients from Ampreloxetine Phase 3 Trials
- Borin M, et al. Abstract 3
A Multiple-dose Thorough QT Study to Evaluate the Effect of Ampreloxetine on Cardiac Repolarization in Healthy Subjects
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.